Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance

PFIZER INC

2024-FY EPS reported $1.41 revenue$63,627,000,000

FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.
FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.
Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.
On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.
Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.